There's a peculiar fact about the $613 billion space economy: some of its most valuable real estate doesn't involve rockets at all. It's the manufacturing zone 250 miles up, where the absence of gravity allows protein crystals to grow with a uniformity that earthbound labs can't match, where semiconductors form with fewer defects, where optical fibers emerge free from the crystallization that bedevils terrestrial production.
None of this is news, exactly. NASA and its partners have been proving microgravity's manufacturing potential aboard the International Space Station since the late 1990s. The challenge—the one that's kept this from becoming an industry rather than a research curiosity—has always been the same: getting the goods back to Earth without obliterating your economics.
Which brings us to Payton Case and Andrew Mello, two former Astranis engineers now running a two-person startup called Dispatch Space out of San Francisco. Their pitch, emerging from Y Combinator's most recent cohort, is straightforward enough to sound almost reckless: heat shields that cost a hundredth of what current alternatives run. They raised $500,000 in pre-seed funding in early 2026 and are aiming for a demonstration flight by mid-2027.
Whether they can actually deliver on that hundred-to-one cost claim remains very much an open question. The shields have been tested against rocket exhaust in Mojave—hardly the same as actual reentry, as any aerospace engineer will tell you. But here's the thing: the market they're chasing is starting to look real.
Money Finds a Thesis
The numbers tell part of the story. According to Tracxn, in-space manufacturing companies have pulled in roughly $397 million across 22 funding rounds as of April this year. That figure is misleading in its modesty—Varda Space Industries alone accounted for $187 million of it with a Series C last July, representing a dominant portion of in-space manufacturing investment in 2025. The concentration reflects both the brutal capital requirements of building orbital infrastructure and a certain investor conviction that yes, some applications can justify the logistics nightmare.
The materials science makes intuitive sense, at least. Without gravity's pull, you eliminate buoyancy-driven convection and sedimentation. Crystallization processes produce structurally distinct products. Between 2017 and 2019, Merck ran Keytruda experiments on the ISS that yielded protein crystals with notably uniform size distributions—work that informed ground-based production rather than producing space-manufactured material for patient markets. Redwire's BioFabrication Facility has printed human meniscus cartilage and live cardiac tissue aboard the station. NASA continues advancing technologies for ZBLAN optical fibers and various advanced materials.
But the ISS is a human-rated research platform, which means constrained power, limited volume, and precious crew time rationed like water in a desert. It's also projected for deorbiting around 2030, subject to ongoing assessments. NASA awarded SpaceX up to $843 million last June to develop the deorbit vehicle that will eventually send the station into the Pacific. Commercial replacements—Axiom's Stallion, Starlab, others—are moving through design reviews, but even optimistic timelines put them operational in the late 2020s. That gap creates urgency for anyone building dedicated manufacturing platforms that don't need life support systems.
Three Shifts, Converging
Several forces are colliding to make orbital manufacturing look less like science fiction and more like, well, difficult business.
Launch costs keep falling, albeit with the usual aerospace drama along the way. Blue Origin's New Glenn managed booster recovery on its debut flight this past January, though an upper-stage anomaly grounded the vehicle by April. SpaceX keeps testing Starship. Even accounting for setbacks—and there are always setbacks—the trajectory bends toward cheaper per-kilogram upmass costs. That math touches every orbital venture's unit economics.
Regulation is catching up, too. The FAA's consolidated Part 450 framework became the sole licensing authority in March, replacing a patchwork of legacy processes with something resembling coherence. Varda Space snagged the first commercial reentry license for a manufacturing capsule in February 2024; its W-1 vehicle landed in Utah a week later. By June of this year, the FAA granted Varda unlimited reentry authority—precedent that theoretically smooths the path for competitors. Environmental assessments for landing sites in Arizona, Nevada, New Mexico, and Oregon are adding to that template.
Then there's the downmass constraint, which is finally easing. For years, SpaceX's Dragon capsules were essentially the only predictable way to return cargo from the ISS. That monopoly is fracturing. Varda's W-Series operates under unlimited reentry authority now. Space Forge, a UK-based competitor, launched its ForgeStar-1 vehicle last June and achieved on-orbit plasma formation by January—a milestone toward growing semiconductor crystals in a dedicated free-flying platform. Sierra Space's Dream Chaser spaceplane is targeting a demonstration later this year. The European Space Agency's ALADDIN program awarded Phase 1 contracts to The Exploration Company and Thales Alenia Space in May 2024, aiming for cargo return demonstrations by decade's end.
Dispatch is placing its bet on cost as the primary variable rather than mass or power. The company's first demonstration vehicle will carry just 30 kilograms in a modest payload envelope—60 by 50 by 30 centimeters—with up to 100 watts of continuous power and mission durations reaching 180 days. Reentry deceleration is specified around 7 g, with payload temperatures held at or below 40°C for about 15 minutes. Recovery within six hours of landing. Those specs suit high-value-density applications: pharmaceuticals, biologics, specialty semiconductors, where a single kilogram of product can justify the entire logistics chain.
The longer-term vision diverges from competitors, though. Rather than scaling individual capsule capacity, Case and Mello plan to deploy uncrewed autonomous stations delivering 100 kilowatts of power by late 2029, serviced by reentry vehicles hauling up to 300 kilograms. The model eliminates human-rating costs—environmental controls, crew operations, safety margins—while supporting energy-intensive processes like semiconductor crystal growth or metal additive manufacturing.
It's ambitious. Perhaps more ambitious than a two-person team emerging from an accelerator would typically attempt as a near-term roadmap, but the space industry has never been accused of thinking small.
The Applications (Such As They Are)
Pharmaceuticals offer the clearest near-term opportunity, in theory. Merck's ISS work on pembrolizumab—marketed as Keytruda—remains the only therapeutic product crystallized in space to date, though it informed terrestrial processes rather than producing space-made drug substance for patients. Varda partnered with Improved Pharma to analyze crystals of ritonavir Form III grown on orbit; analyses from last year suggested feasible transformation and stability. But the regulatory pathway remains the real gatekeeper. Satisfying FDA standards for investigational new drugs, new drug applications, or biologics license applications adds both lead time and compliance costs that could overwhelm even superior crystallization.
Bioprinting runs parallel. Redwire's BioFabrication Facility printed human knee meniscus on the ISS in September 2023 and live human cardiac tissue last May. LambdaVision has completed nine ISS missions developing its artificial retina via layer-by-layer manufacturing and has reserved time on Starlab once—if—that commercial destination becomes operational. These are demonstrations rather than commercial products, but they establish technical feasibility for scaffold-free biofabrication that gravity makes impossible.
Semiconductors face steeper hurdles. A meta-analysis published in npj Microgravity last year, reviewing semiconductor materials grown in microgravity, reported mixed improvements, with crystal size showing the least consistent gains. The authors emphasized the need for rigorous process control and standardized metrics—a polite way of saying that microgravity is an enabling condition, not a magic wand. Space Forge's ForgeStar-1, which achieved plasma ignition in orbit earlier this year, aims to address this through dedicated, lights-out manufacturing runs of silicon carbide and gallium arsenide. The company's foldable "Pridwen" heat shield underwent parabolic flight deployments in 2025, targeting full reusability to spread capsule costs across multiple missions.
Optical fibers represent the most mature application—relatively speaking. NASA's In-Space Production Applications partners, including FOMS, Flawless Photonics, and Mercury Systems, have conducted repeated ZBLAN fiber draws on the ISS. NASA reported "extraordinary accomplishments" in a technical document last July. ZBLAN, a fluoride glass, suffers from crystallization defects during terrestrial production that microgravity suppresses. Multiple missions in 2024 and 2025 produced fibers for evaluation toward commercial-scale manufacturing, though what "commercial-scale" means in this context remains undefined.
Compressed Timelines
The industry seems to be settling into a two-tier model. High-value, low-mass applications—select pharmaceuticals, biologics, specialty optics—will likely flow through dedicated capsules optimizing for cost per mission rather than aggregate throughput. Bulk materials and energy-intensive processes may migrate to larger uncrewed platforms with docking infrastructure, the kind of architecture Dispatch is sketching out for the late 2020s.
The ISS endgame compresses timelines considerably. Station retirement in 2030 is fixed policy, underscored by that $843 million deorbit contract. Commercial destination maturity is uneven. Starlab passed NASA's Commercial Critical Design Review in February, advancing toward manufacturing and integration, but first operations likely arrive in 2028 or 2029 at best. Any delays in commercial destination readiness could create a capacity gap between 2028 and 2031—risk for some, opportunity for free-flying platforms that don't depend on docking infrastructure.
Market projections reflect cautious optimism, or perhaps optimistic caution. The Space Foundation valued the global space economy at $613 billion in 2024, with data reported in July 2025. A World Economic Forum and McKinsey study projects $1.8 trillion by 2035, incorporating both "backbone" satellite and launch services and "reach" applications like orbital manufacturing. Precedence Research forecasts in-space manufacturing services specifically could hit $11.7 billion by 2035.
Those are analyst estimates with proprietary methodologies, not established markets. But they signal directional conviction, which matters when you're trying to raise capital for a venture that involves, among other things, building autonomous space stations.
What Comes Back Down
Regulatory questions linger. FDA pathways for space-manufactured drugs demand the same evidentiary standards as terrestrial products—no shortcuts for novelty. Export controls under ITAR Category XV cover spacecraft systems and reentry components, complicating international partnerships. Launch market volatility persists despite cost trends; New Glenn's April grounding demonstrated schedule risk remains embedded in the ecosystem. Still, Part 450's streamlining and early operator precedents are reducing regulatory novelty with each successive license.
Dispatch's first flight will test both its heat shield economics and market appetite for dedicated microgravity return services. The company enters a field with well-capitalized competitors—Varda's war chest buys considerable runway. But there's also distinct technical and business model differentiation, assuming the heat shields perform as advertised.
Whether those shields can truly cost a hundredth of current alternatives won't be measured in rocket-exhaust tests in Mojave. It'll be measured in recovered payloads and repeat customers—in the unglamorous work of making the economics actually work. Because here's what the space manufacturing industry is learning, slowly and expensively: the value isn't in reaching orbit.
It's in what comes back down.
